---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Dosage forms and strengths"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Dosage forms and strengths. Topics: Capsules given fasted in the phase 1/2 monotherapy study, Daily doses studied in dose escalation, Capsule formulation and gastrointestinal events; tablet formulation in ongoing studies, Tablet formulation in OPERA-01, and 2 further topics. 6 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description/dosage-forms-and-strengths"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Dosage forms and strengths

<a id="heading-2.1.2.2"></a>

## 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

### Commercial dosage form and strength

No evidence found.

<a id="topic-2.1.2.2-2"></a>

### Capsules given fasted in the phase 1/2 monotherapy study

> “All patients received oral palazestrant capsules once daily, continuously in 28-day treatment cycles. In this first-in-human study, patients were required to fast for 2 h prior to and 1 h after each palazestrant dose.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.2-3"></a>

### Daily doses studied in dose escalation

> “The initial dose cohort received a dose of palazestrant at 30 mg/day, followed by dose cohorts of 60, 90, 120, 150, 210, and 300 mg/day.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.2-4"></a>

### Capsule formulation and gastrointestinal events; tablet formulation in ongoing studies

> “the drug was administered in a relatively large capsule formulation, each of which could have contributed to an increased incidence of gastrointestinal events. Ongoing studies are using a tablet formulation, allowing drug administration in the fed state, and using anti-emetic medications when needed that may reduce frequency of nausea, vomiting, and fatigue”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.2-5"></a>

### Tablet formulation in OPERA-01

> “In OPERA-01 pivotal Phase 3 trial, patients are receiving tablet formulation instead of the capsules utilized in current dataset”
> “Expected to reduce rate and grade of nausea and vomiting”

Source: [Olema Oncology corporate presentation (2026)](https://ir.olema.com/static-files/0669229e-3ae2-4bed-a1ce-308627866d06)

<a id="topic-2.1.2.2-6"></a>

### Capsules in the ribociclib combination analysis

> “Palazestrant was administered in capsules and in fasting state in this analysis.”

Source: [Borges et al. (2024a)](https://olema.com/wp-content/uploads/2024/05/Olema_Final_ESMO-Breast-2024_OP-1250-003_5-15-24.pdf)

<a id="topic-2.1.2.2-7"></a>

### Doses in the phase 3 trials: 90 mg and 120 mg once daily in OPERA-01 Part 1; 90 mg once daily in OPERA-02

> “Participants will be treated with palazestrant once daily on a 4 week (28 day) cycle. Doses evaluated in the dose-selection part will be 120 mg once daily and 90 mg once daily.”

Source: [ClinicalTrials.gov NCT06016738](https://clinicaltrials.gov/study/NCT06016738)

> “Participants will be treated with palazestrant 90 mg once daily on a 4-week (28-day) cycle.”

Source: [ClinicalTrials.gov NCT07085767](https://clinicaltrials.gov/study/NCT07085767)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
